Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine?

<table>Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of recurrent new<i> falciparum</i> infection at day 42.</table>

Malaria Research and Treatment

fig6

Figure 6

Figure 6: Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine? 

Figure 6 | Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? 